Home › Funds › ARMISTICE CAPITAL, LLC › NTLA
ARMISTICE CAPITAL, LLC position in NTLA
INTELLIA THERAPEUTICS INC · Health Care
ARMISTICE CAPITAL, LLC reported holding 1,500,000 shares of NTLA (INTELLIA THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$25.4M, representing 0.33% of its reported portfolio and ranking #43 among its reported holdings. ARMISTICE CAPITAL, LLC has disclosed NTLA holdings in 6 of the last 6 reported quarters, going back to Q1 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How ARMISTICE CAPITAL, LLC's NTLA position evolved
ARMISTICE CAPITAL, LLC first disclosed a stake in NTLA in Q1 2025 at 364,000 shares (US$2.6M). The position peaked in Q2 2026 at 1,500,000 shares, worth US$25.4M. Across 6 filings, ARMISTICE CAPITAL, LLC increased the stake 4 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 1,500,000 shares valued at US$25.4M — an increase of 1,164,000 shares quarter over quarter.. Notable position changes include a 79% increase in Q2 2025 (shares rose 84% over the following quarter), a 72% increase in Q4 2025 (shares rose 43% over the following quarter), a 346% increase in Q2 2026 (shares fell 29% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2025 | 364.00K | $2.59M | New |
| Q2 2025 | 650.00K | $6.10M | Add |
| Q3 2025 | 672.00K | $11.61M | Add |
| Q4 2025 | 1.16M | $10.39M | Add |
| Q1 2026 | 336.00K | $4.31M | Reduce |
| Q2 2026 | 1.50M | $25.38M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About NTLA and 13F data
NTLA (INTELLIA THERAPEUTICS INC) is a Health Care company. 38 other funds we track also report a position in NTLA — the largest reported positions include ARK Invest (US$285.5M), RA CAPITAL MANAGEMENT, L.P. (US$76.6M), REGENERON PHARMACEUTICALS, INC. (US$62.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding NTLA
- ARK Invest 16.88M sh · $285.54M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 4.53M sh · $76.60M · Q2 2026
- REGENERON PHARMACEUTICALS, INC. 3.70M sh · $62.65M · Q2 2026
- Amova Asset Management Americas, Inc. 2.90M sh · $49.03M · Q2 2026
- Contrarius Group Holdings Ltd 1.96M sh · $33.08M · Q2 2026
- Ghisallo Capital Management LLC 1.20M sh · $20.30M · Q2 2026
- IQ EQ FUND MANAGEMENT (IRELAND) Ltd 777.95K sh · $13.16M · Q2 2026
More on ARMISTICE CAPITAL, LLC
FAQ
How long has ARMISTICE CAPITAL, LLC held NTLA?
ARMISTICE CAPITAL, LLC has disclosed NTLA holdings in 6 of the last 6 reported quarters, going back to Q1 2025.
What is ARMISTICE CAPITAL, LLC's current position in NTLA?
As of Q2 2026, ARMISTICE CAPITAL, LLC holds 1.50M shares of NTLA (INTELLIA THERAPEUTICS INC), valued at $25.38M, representing 0.33% of its reported portfolio and ranking #43.
Has ARMISTICE CAPITAL, LLC been buying or selling NTLA?
In the latest 13F filing (Q2 2026), ARMISTICE CAPITAL, LLC increased its position in NTLA. The position peaked in Q2 2026 at 1.50M shares.
Which other funds hold NTLA?
Other major institutional holders of NTLA include ARK Invest, RA CAPITAL MANAGEMENT, L.P., REGENERON PHARMACEUTICALS, INC., among 38 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.